MEK or ERK inhibition in HPV-transformed cancers may offer the benefit of anti-viral effects by reducing viral oncoprotein activities and restoring tumor suppressor functions in addition to generally suppressing cellular proliferation; the former mechanisms may yield distinct advantages in treating HPV-positive cancers. The gene discussed is MAP2K7; the disease is cancer.